[Complex treatment of inflammatory breast cancer]

Abstract

Inflammatory breast cancer represents 2-5% of all malignant breast lesions. Its rapid progression, the rather short medical history of the disease is unique and seems to be very typical. The combined modality treatment of inflammatory breast cancer is a special challenge for the medical oncologists. Preoperative chemotherapy is of great importance. After getting fair remission, surgery and radiotherapy should be delivered. With combined modality therapy the 5-year overall survival is about 50%. Knowing more pharmaco-genomic details on the disease and delivering new medicaments the effectiveness of the treatment will be further enhanced.